Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 10mg | $28.00$16.80 | $1.68/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| 04-25-0510C | Jun 2025 | 100.0% | Janoshik Analytical | — | Unverified | View |
| 08-24-0405B | Oct 2024 | 99.3% | Janoshik Analytical | — |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHRP-6 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Verified Peptides sell GHRP-6?
Yes — Verified Peptides currently lists GHRP-6 in 1 variant starting at $16.80 ($1.68/mg).
Is Verified Peptides's GHRP-6 third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for Verified Peptides's GHRP-6, with the most recent showing 100.0% purity. Verified Peptides holds an overall trust grade of C (79/100) across all 364 COAs on file.
What is Verified Peptides's trust grade for GHRP-6?
Verified Peptides has an overall Disclosed Labs trust grade of C (79/100), computed from 364 COAs across all peptides. The most recent GHRP-6 COA was issued by Janoshik Analytical.
Where is the cheapest GHRP-6?
As of the latest data, Moglabs offers GHRP-6 at $2.40/mg — compare with Verified Peptides's listing at $1.68/mg. See the full GHRP-6 price comparison.
Is GHRP-6 legal to buy?
GHRP-6 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| Unverified |
| View |
Disclosed Labs